Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mild-to-moderate Essential Hypertension”

67 trials

Showing 20 of 67 results

Testing effectiveness (Phase 2)Study completedNCT00362115
What this trial is testing

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

Who this might be right for
Hypertension
Takeda 449
Post-approval studies (Phase 4)Study completedNCT00302705
What this trial is testing

Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose

Who this might be right for
Hypertension
University of Vigo 150
Large-scale testing (Phase 3)Study completedNCT05385770
What this trial is testing

Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

Who this might be right for
Essential Hypertension
Celltrion 890
Testing effectiveness (Phase 2)Study completedNCT00922441
What this trial is testing

A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Who this might be right for
Essential Hypertension
Boryung Pharmaceutical Co., Ltd 92
Large-scale testing (Phase 3)Study completedNCT00872586
What this trial is testing

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

Who this might be right for
Essential Hypertension
Daiichi Sankyo 304
Testing effectiveness (Phase 2)Study completedNCT01878201
What this trial is testing

A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Who this might be right for
Essential Hypertension
Boryung Pharmaceutical Co., Ltd 75
Large-scale testing (Phase 3)Study completedNCT00400218
What this trial is testing

Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)

Who this might be right for
Hypertension
Organon and Co 62
Post-approval studies (Phase 4)Study completedNCT00765947
What this trial is testing

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

Who this might be right for
Essential Hypertension ( Mild to Moderate)
Novartis 256
Testing effectiveness (Phase 2)Study completedNCT01303783
What this trial is testing

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

Who this might be right for
Hypertension, Essential
Bayer 1,381
Large-scale testing (Phase 3)Study completedNCT00151827
What this trial is testing

Olmesartan Medoxomil in Hypertension and Renal Impairment

Who this might be right for
Essential HypertensionRenal Impairment
Sankyo Pharma Gmbh 393
Post-approval studies (Phase 4)Study completedNCT00473174
What this trial is testing

Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension

Who this might be right for
Hypertension
University of Vigo 120
Post-approval studies (Phase 4)Study completedNCT00861016
What this trial is testing

Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension

Who this might be right for
Hypertension
AstraZeneca 310
Testing effectiveness (Phase 2)Study completedNCT01281306
What this trial is testing

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

Who this might be right for
Systolic Hypertension
Novartis Pharmaceuticals 910
Post-approval studies (Phase 4)Study completedNCT00311155
What this trial is testing

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension

Who this might be right for
Essential Hypertension
Sankyo Pharma Gmbh 694
Post-approval studies (Phase 4)Study completedNCT00130156
What this trial is testing

Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension

Who this might be right for
High Blood Pressure
Eisai Inc. 93
Not applicableStudy completedNCT02336607
What this trial is testing

The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.

Who this might be right for
Hypertension
AstraZeneca 529
Large-scale testing (Phase 3)Study completedNCT00922480
What this trial is testing

Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients

Who this might be right for
Hypertension
Boryung Pharmaceutical Co., Ltd 506
Large-scale testing (Phase 3)Study completedNCT02183701
What this trial is testing

Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

Who this might be right for
Hypertension
Boehringer Ingelheim 715
Large-scale testing (Phase 3)Study completedNCT02206659
What this trial is testing

Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension

Who this might be right for
Hypertension
Boehringer Ingelheim 20
Testing effectiveness (Phase 2)Study completedNCT00923611
What this trial is testing

Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients

Who this might be right for
Hypertension
Boryung Pharmaceutical Co., Ltd 182
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation